DVL3

Across TCGA pan-cancer cohorts, DVL3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DVL3 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DVL3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DVL3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where DVL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.214	0.785	.006	26	view →
HNSC	DFS	Tertile	All	0.991	0.872	.003	21	view →
LSCC	OS	Median	II,III,IV	0.655	0.873	.019	12	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	7	view →
LUAD	DFS	Tertile	All	0.952	0.882	.016	7	view →
UCEC	DFS	Median	All	0.957	0.855	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DVL3–PDAC (DFS)

Open the PDAC breakdown →